Eli Lilly confirms weight loss drug agreement with U.S. government

Eli Lilly (LLY) announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. Lilly said it will now improve access to nearly 40M Americans living with obesity on government insurance programs “and millions more who pay out-of-pocket.” Starting as early as April 1, 2026, Medicare beneficiaries will pay no more than $50 per month for Zepbound, available in a multi-dose pen, and for orforglipron, Lilly’s once-daily obesity pill, provided both receive approval from the Food and Drug Administration. Upon FDA approval, self-pay patients living with obesity will be able to access these medicines through LillyDirect’s self-pay pharmacy channel. Zepbound multi-dose pen will be available at the lowest dose at $299, with additional doses up to $449 representing a $50 discount to current direct-to-patient prices. Lilly will also continue to offer insulin at no more than $35 per month out-of-pocket, whether a person has commercial insurance or no insurance.